August 21, 2018 Nanjing, ChinaFrontier Biotech announced today its IND of novel long-acting, all-injectable anti-HIV two drug combo (albuvirtide for injection, ABT and 3BNC117) was allowed by the US FDA on August 14th 2018, and the company will start a phase II clinical trial of the combo therapy in...
  • 2018-08-21  11:00:35
June 5, 2018 Nanjing, ChinaFrontier Biotechnologies Inc. (Frontier Biotech), a leading science-driven biopharmaceutical company in China, announced today that China Food and Drug Administration (CFDA) has granted marketing authorization for Aikening® (albuvirtide for injection, ABT), Chinas fir...
  • 2018-06-07  11:00:05
2018-04-02 16:37:25Dr. Jing Bao was appointed to Vice President Clinical Development at Frontier Biotech. Dr. Bao has 16 years’ experience in global clinical trials oversight, scientific administration, pharmacovigilance, technology transfer, and 10 years’ experience as a practicing physician. Prio...
  • 2010-04-07  10:59:39
March 5th, 2018 NanjingDr. Huyi (John) Zhang, was appointed as Vice President of Regulatory Affairs. Dr. Zhang is an expert in drug registration and regulatory science with rich experience in drug discovery and development. Prior to joining Frontier Biotech, he was Head of Regulatory Affairs at Sim...
  • 2018-03-05  10:59:09
The HIV Forum on “bNAbs and Functional Cure” was successfully held by Tsinghua University and Frontier Biotech on Nov 28, 2017 in Beijing. Coming with the 30th World AIDS Day, this event was focused on the latest research of broad neutralizing antibodies (bNAbs) and long-acting drug regimen for HIV ...
  • 2017-12-20  10:58:36
Nanjing, China July17, 2017 – Frontier Biotechnologies, Inc., a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing significant unmet medical needs, today announced it has signed an agreement with The Rockefeller University of the US for...
  • 2017-07-25  10:56:07
On December 31, 2016 in Nanjing, Jiangsu, FRONTIER BIOTECHNOLOGIES, INC.(“Frontier Biotech”) announced completion of 300 million yuan C financing. This investment was led by Huaxin Century Investment Group Co., Ltd. (abbreviated as “Huaxin Century”) and funded jointly by Shenzhen Capital Group Co....
  • 2017-01-17  10:55:39
On November 23, 2016, the new generation of anti-HIV drug (HIV fusion inhibitor - Albuvirtide) debuted. Albuvirtide was independently researched and developed by Chinese scientists with the support of national major scientific and technological project. NDA was accepted by SFDA. With the guidance of...
  • 2017-01-17  10:55:03
2016 HIV Medicine Therapy Conference was held in Glasgow, UK from October 23 to 26. Dr. Dong Xie, founder of Frontier Biotech and Chief Scientist, was invited to address a TALENT research themed speech. TALENT study is phase III of the first licensing study of a new antiretroviral drug conducted in ...
  • 2017-01-17  10:54:33

Innovative solutions to promote human health